Preliminary results of the clinical study on the diagnosis of lung cancer patients show 4D Lifetest™ having a competitive or better sensitivity and specificity compared to leading diagnostic biomarkers for lung cancer. This is really another important breakthrough on the way to an effective multi-cancer assay.
We congratulate the entire team of the company for reaching this extremely important milestone.
With many exciting discussions at the JPM conference in San Francisco, 4D Lifetec has started to focus on the USA market entry.
We are very pleased that we were able to close the year 2019 with positive results. The results confirms our conviction that the 4D LifetestTM will soon reach the next important milestone.
After reaching Proof of Technology in August the 4D Lifetec team is exited to announce the successful reach of the next milestone by entering into the clinical study with the 4D Lifetest™.
Please read an update on the highlights of our newest scientific publication from EMPA and 4D Lifetec. Our innovative 4D Lifetest™ has now been officially qualified to meet the high expectations announced and revolutionize the possible applications of SCGE towards the use in diagnostics.
As a awarded winner 4D Lifetec became part of the Venture Leaders Life Science Group 2019 and was invited to travel to Boston (USA).
Arne Faisst, our CEO, tells more about our plans in the US
Please vote for 4D Lifetec.
4D Lifetec AG recently opened the funding round C1.
4D Lifetec AG has started the early cancer diagnostic validation program for its integral liquid biopsy assay 4D Lifetest™.
4D Lifetec has been recognized and selected out of approximately 200 applications for the W.A. de Vigier Start-up Award.
Thank you for visiting 4D Lifetec at the SOT.
After some intense months the prototype phase for the 4D Lifetank has been completed by the end of 2016.
A cancer research center in France was able to generate high precise data using their own cells.
4D Lifetest™ yields to much better results than expected.
4D Lifetec AG has successfully closed capital phase B2. All investors, including new investors represent private investors and business angels.
Following the communication a few days back, 4D Lifetec now officially communicates the positive outcome of the release testing procedure for the first 4D LifetestTM equipments at the Swiss Federal Laboratories for Materials Testing and Research (Empa).
4D Lifetec proudly announces the finalisation of the first industrially designed and fully functional prototypes of its automated high precision and GLP standardised Single Cell Gel Electrophoresis equipment, the so-called “4D LifetestTM”.
At the J.P. Morgan Health Care Conference in January this year, liquid biopsies were mentioned as „a revolutionary blood test that can detect cancer” [1]. Currently, local media (such as Handelsblatt[2]) mention this method having a breakthrough character.
Advances in genetic science enable researchers to detect genetic mutations of cancers. Unique mutations of patient’s blood can give experts a sign of the presence of cancer. These DNA mutations can be found in cells or they are floating freely in the bloodstream. Liquid biopsies - unlike traditional biopsies involving invasive surgery - therefore rely on an ordinary blood draw.
Our CTI Project application with the Number 18535.1 PFLS-LS and the title: “4D Lifestandard - a biological standardization kit for genotoxicity testing” has been successfully approved.
4D Lifetec successfully applied for the 2015 Zuger Innovationspreis.
4D Lifetec AG has successfully closed capital raising phases A and B1.
